BCRX · Biocryst Pharmaceuticals Inc
United States · RS rating 42 · As of 2026-10-14
| Price | 8.05 USD |
|---|---|
| 1-day change | -0.2% |
| RS rating (overall / 1M / 3M / 12M) | 42 / 57 / 29 / 66 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 41 / 26 / 49 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +1766.7% |
| Sales growth Q/Q | +155.1% |
| Distance from 52-week high | +27.5% |
| Market cap (USD) | $2.2B |